Compare Nucor Corporation (NUE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs GeneDx Holdings Corp — how do they compare? Nucor Corporation trades at $270.61 (market cap $61.93B), while GeneDx Holdings Corp trades at $82.15 (market cap $2.44B). The key difference: Nucor Corporation is far larger — about 25.4× GeneDx Holdings Corp's market cap, and Nucor Corporation pays a 0.82% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NUE | WGS | |
|---|---|---|
Market Cap | $61.93B | $2.44B |
Sector | Basic Materials | Technology |
52-Week High | $274.74 | $167.51 |
52-Week Low | $131.78 | $34.51 |
Enterprise Value | $66.34B | $2.48B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $269.50, down 1.86% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings with EPS of $4.84 beating estimates of $4.46, driven by record steel mill shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections indicating $36.1B revenue and improved margins. Analyst consensus remains positive with 59% buy ratings and a $279.63 price target, representing 3.8% upside potential.
Nucor presents a compelling investment case with earnings momentum, favorable analyst sentiment, and technical strength. Key opportunities include continued demand recovery and operational efficiency gains. However, risks include cyclical steel industry exposure, tariff policy uncertainties, and declining operating cash flow trends from 2022 peaks. The stock offers moderate upside to consensus targets but faces macroeconomic headwinds affecting industrial demand.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
